Research Article

CLINICOPATHOLOGICAL CHARACTERISTICS OF BREAST CANCER PATIENTS WHO PRESENTED AT A SOUTHWESTERN NIGERIAN RADIATION ONCOLOGY CLINIC

Bolaji L. Salako1, Abbas A Abdus-Salam2, Ajibike A. Orekoya3*, Adeniyi A Olabumuyi2, Sharif A. Folorunso4, Adeniyi Adenipekun2, Atara I Ntekim2, Babatunde O Ogunnorin2, Oladeji Afolabi adebayo2, Jimoh mutiu alani2, Foluke O. Sarimiye5, Ayorinde M. Folasire6
1 Federal Medical Centre, Abeokuta, Ogun State
2 Radiation Oncology Department, University College Hospital, Ibadan, Oyo State, Nigeria
3 Federal Medical Centre, Ebute-Metta, Lagos State, Nigeria
4 Department of Radiation Oncology, Obafemi Awolowo University Teaching Hospital, Ile-Ife.
5 Department of Radiation Oncology, University of Ibadan/University College Hospital (UCH), Ibadan, Oyo State, Nigeria
6 Department of Radiation Oncology, College of Medicine, University of Ibadan, Nigeria
* Corresponding author: mailjibike3@gmail.com
Published: Feb, 2026
DOI: 10.67579/njo.2026.xabxossl
Pages: 1-14
Views: 357
Downloads: 131

Abstract

Background: Breast cancer is the commonest female cancer in Nigeria and is also the commonest cause of cancer mortality among Nigerian females. Although the incidence is not as high as the average worldwide incidence rate, the mortality of breast cancer patients in Nigeria is high.
 
Objective: We analysed the sociodemographic and clinicopathological characteristics of breast cancer patients who presented at the Radiation Oncology Clinic, University College Hospital, Ibadan, Nigeria.
 
Methods: This was a retrospective cross-sectional study. Sociodemographic and clinicopathological details were obtained from the case notes of breast cancer patients who presented at the Radiation Oncology Clinic, University College Hospital, Ibadan, from January 2008 to December 2017.
Results: A total of 605 patients were included. There were 8 men. The age of patients ranged from 28 to 90 years, with a mean age of 48.2 ± 9.2 years. Most were middle-aged and had semi-skilled employment. A considerable proportion had early menarche, high parity, and prolonged breastfeeding. Clinically, most patients presented with left-sided disease at an advanced stage (stage III or IV). Invasive ductal carcinoma (most commonly moderately differentiated) was the most common histological subtype. Among those who had immunohistochemistry done, triple-negative and HER2-enriched subtypes were most frequent.
 
Conclusion: These findings underscore the need for early detection strategies and expanded access to diagnostic tools like immunohistochemistry. Addressing these gaps is essential to improving treatment outcomes and survival in breast cancer patients in Nigeria.

Keywords

breast neoplasms immunohistochemistry clinicopathology sociodemographic factors radiotherapy department pathology delayed diagnosis Nigeria

References

  1. 20-breast-fact-sheet.pdf [Internet]. [cited 2025 Feb 25]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf
  2. 566-nigeria-fact-sheet.pdf [Internet]. [cited 2025 Feb 25]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/566-nigeria-fact-sheet.pdf
  3. Martei YM, Pace LE, Brock JE, Shulman LN. Breast cancer in low-and middle-income countries: why we need pathology capability to solve this challenge. Clinics in laboratory medicine. 2017;38(1):161.
  4. Agboola AJ, Musa AA, Wanangwa N, Abdel-Fatah T, Nolan CC, Ayoade BA, et al. Molecular characteristics and prognostic features of breast cancer in Nigerian women compared with UK women. Breast Cancer Res Treat. 2012 Sep;135(2):555–69.
  5. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. American journal of epidemiology. 1994;139(8):819–35.
  6. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. American journal of epidemiology. 2000;152(10):950–64.
  7. Ritte R, Lukanova A, Tjønneland A, Olsen A, Overvad K, Mesrine S, et al. Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: A cohort study. Intl Journal of Cancer. 2013 Jun;132(11):2619–29.
  8. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic Density and the Risk and Detection of Breast Cancer. N Engl J Med. 2007 Jan 18;356(3):227–36.
  9. Wong CS, Lim GH, Gao F, Jakes RW, Offman J, Chia KS, et al. Mammographic density and its interaction with other breast cancer risk factors in an Asian population. British journal of cancer. 2011;104(5):871–4.
  10. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. Jama. 2011;306(17):1884–90.
  11. Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. Active smoking and breast cancer risk: original cohort data and meta-analysis. Journal of the National Cancer Institute. 2013;105(8):515–25.
  12. Lahmann PH, Hoffmann K, Allen N, Van Gils CH, Khaw K, Tehard B, et al. Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC). Intl Journal of Cancer. 2004 Sep 20;111(5):762–71.
  13. Adebamowo CA, Ogundiran TO, Adenipekun AA, Oyesegun RA, Campbell OB, Akang EE, et al. Waist–hip ratio and breast cancer risk in urbanized Nigerian women. Breast Cancer Res 2002 Dec 19;5(2):R18.
  14. Adebamowo CA, Ogundiran TO, Adenipekun AA, Oyesegun RA, Campbell OB, Akang EU, et al. Obesity and height in urban Nigerian women with breast cancer. Annals of epidemiology. 2003;13(6):455–61.
  15. Breast Cancer Risk Factors: Practice Essentials, Background, Incidence and Mortality, Overview. 2025 Mar 28 [cited 2025 May 18]; Available from: https://emedicine.medscape.com/article/1945957-overview?form=fpf
  16. Colditz GA, Rosner B, Hankinson SE. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. American journal of epidemiology.
  17. Gram IT, Park SY, Kolonel LN, Maskarinec G, Wilkens LR, Henderson BE, et al. Smoking and risk of breast cancer in a racially/ethnically diverse population of mainly women who do not drink alcohol: the MEC study. American journal of epidemiology. 2015;182(11):917–25.
  18. Sipitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathological features and short-term survival analysis in a population-based study from the South of Switzerland. Annals of Oncology. 2009;20(4):628–35.
  19. Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, et al. Breast cancer classification according to immunohistochemistry: subtypes and association with clinicopathologic variables in a Peruvian hospital database. Clinical breast cancer. 2010;10(4):294–300.
  20. Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. American journal of cancer research. 2015;5(10):2929.
  21. Sinn HP, Kreipe H. A brief overview of the WHO classification of breast tumors, focusing on issues and updates from the 3rd edition. Breast care. 2013;8(2):149–54.
  22. Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. nature. 2000;406(6797):747–52.
  23. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001 Sep 11;98(19):10869–74.
  24. Russnes HG, Lingjærde OC, Børresen-Dale AL, Caldas C. Breast cancer molecular stratification: from intrinsic subtypes to integrative clusters. The American journal of pathology. 2017;187(10):2152–62.
  25. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Human pathology. 2007;38(8):1105–22.
  26. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subgroups—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology. 2011;22(8):1736–47.
  27. Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR. Molecular classification of breast cancer. Virchows Arch. 2014 Jul;465(1):1–14.
  28. Lips EH, Mulder L, De Ronde JJ, Mandjes IAM, Koolen BB, Wessels LFA, et al. Breast cancer subtyping by immunohistochemistry and histological subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013 Jul;140(1):63–71.
  29. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama. 2006;295(21):2492–502.
  30. Ndom P, Um C, Bell EMD, Eloundou A, Hossain NW, Huo D. A meta-analysis of
  31. male breast cancer in Africa. The Breast. 2012;21(2):237–41.
  32. Ajani MA, Odetola SA, Awosusi BL, Fatunla EO, Salami AA. Histopathological analysis of male breast cancer in Southwestern Nigeria: A single-centre retrospective study. Journal of Clinical Sciences. 2021;18(2):113–6.
  33. Sabahi SM, Abdullahi K. Histopathological review of male breast cancer in Sokoto, Nigeria. Annals of Tropical Pathology. 2017;8(2):108–11.
  34. Dogo D, Gali DI, Ali N, Nggada HA. Male breast cancer in north eastern Nigeria. Nigerian journal of clinical practice. 2006;9(2):139–41.
  35. Ihekwaba FN. The management of male breast cancer in Nigerians. Postgraduate Medical Journal. 1993;69(813):562–5.
  36. Ahmed A, Ukwenya Y, Abdullahi A, Muhammad I. Management and outcomes of male breast cancer in Zaria, Nigeria. International journal of surgery. 2012;2012.
  37. Ottini L, Ottini L, Capalbo, Rizzolo, Silvestri V, Rizzo, et al. HER2-positive male breast cancer: update. BCTT. 2010 Oct;45.
  38. Oguntola AS, Aderonmu AO, Adeoti ML, Olatoke SA, Akanbi O, Agodirin SO. Male breast cancer in LAUTECH teaching hospital, Osogbo, South Western Nigeria. Niger Postgrad Med J. 2009;16(2):166–70.
  39. Ezeome ER, Emegoakor CD, Chianakwana GU, Anyanwu SNC. The pattern of male breast cancer in eastern Nigeria: A 12-year review. Nigerian Medical Journal. 2010;51(1):26.
  40. Collaborative Group on Hormonal Factors in Breast Cancer: Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001 Oct 27;358(9291):1389–99.
  41. Factors that modify breast cancer risk in women - UpToDate [Internet]. [cited 2025 Feb 15]. Available from: https://www.uptodate.com/contents/factors-that-modify-breast-cancer-risk-in-women#H1792871017
  42. Ogundiran TO, Ayandipo OO, Ademola AF, Adebamowo CA. Mastectomy for management of breast cancer in Ibadan, Nigeria. BMC Surg. 2013 Dec;13(1):59.
  43. Kene TS, Odigie VI, Yusufu LM, Yusuf BO, Shehu SM, Kase JT. Pattern of presentation and survival of breast cancer in a teaching hospital in North-Western Nigeria. Oman Medical Journal. 2010;25(2):104.
  44. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008 Jul;110(1):183–8.
  45. Gukas ID, Jennings BA, Mandong BM, Igun GO, Girling AC, Manasseh AN, et al. Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West African journal of medicine. 2005;24(3):209–13.
  46. Folasire A, Folorunso S, Orekoya A, Ehiedu C, Olabumuyi A, Ntekim A. Pattern and outcome of admission of cancer patients at radiation oncology ward, University College Hospital, Ibadan, Nigeria. Journal of Radiation Medicine in the Tropics. 2020;1(2):67–71.
  47. Ali-Gombe M, Mustapha MI, Folasire A, Ntekim A, Campbell OB. Pattern of survival of breast cancer patients in a tertiary hospital in South West Nigeria. ecancermedicalscience. 2021;15:1192.
  48. Olopade OI, Ikpatt FO, Dignam JJ, Khramtsov A, Tetriakova M, Grushko T, et al. Intrinsic Gene Expression subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumours among black women of African ancestry. JCO. 2004 Jul 15;22(14_suppl):9509–9509.
  49. Chen L, Li CI. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer epidemiology, biomarkers & prevention. 2015;24(11):1666–72.
  50. New survey results indicate that Nigeria has an HIV prevalence of 1.4% | UNAIDS [Internet]. [cited 2025 Jul 18]. Available from: https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2019/march/20190314_nigeria
  51. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. JCO. 2013 Nov 1;31(31):3997–4013.
  52. Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Archives of Pathology & Laboratory Medicine. 2023 Sep 1;147(9):993–1000.
  53. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene. Science. 1987 Jan 9;235(4785):177–82.
  54. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer. Science. 1989 May 12;244(4905):707–12.
  55. Emmanuel I, Mandong BM, Kwaghe BV, Yakubu D. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 status of breast cancers in women visiting the Jos University Teaching Hospital. Annals of Nigerian Medicine. 2017;11(1):22–6.
How to Cite

Salako, B. L., Abdus-Salam, A. A., Orekoya, A. A., Olabumuyi, A. A., Folorunso, S. A., Adenipekun, A., Ntekim, A. I., Ogunnorin, B. O., adebayo, O. A., alani, J. M., Sarimiye, F. O., & Folasire, A. M. (2026). CLINICOPATHOLOGICAL CHARACTERISTICS OF BREAST CANCER PATIENTS WHO PRESENTED AT A SOUTHWESTERN NIGERIAN RADIATION ONCOLOGY CLINIC. Nigerian Journal of Oncology, 2(1), 1-14. https://doi.org/10.67579/njo.2026.xabxossl

B. L. Salako, A. A. Abdus-Salam, A. A. Orekoya, A. A. Olabumuyi, S. A. Folorunso, A. Adenipekun, A. I. Ntekim, B. O. Ogunnorin, O. A. adebayo, J. M. alani, F. O. Sarimiye, and A. M. Folasire, "CLINICOPATHOLOGICAL CHARACTERISTICS OF BREAST CANCER PATIENTS WHO PRESENTED AT A SOUTHWESTERN NIGERIAN RADIATION ONCOLOGY CLINIC," Nigerian Journal of Oncology, vol. 2, no. 1, pp. 1-14, February 2026. doi: 10.67579/njo.2026.xabxossl

Share this article:
Facebook X / Twitter LinkedIn
Download PDF View Full Text (PDF) Back to Articles